LTB4R and myeloid sarcoma: Specific BLT1 blocking or preventing LTB4 biosynthesis may, therefore, be considered as potent therapeutic strategies, especially during the early stages of MS pathology, which are dominated by profound lymphocyte CNS infiltration.